Want to see SE:ANNX full AI Analyst Report?

Annexin Pharmaceuticals AB (ANNX) Price & Analysis

2 Followers

ANNX Stock Chart & Stats

kr19.90

kr0.01(3.44%)

At close: Mar 06 4:00 PM EST

kr19.90

kr0.01(3.44%)

Day’s Range― - ―

52-Week Rangekr11.05 - kr35.27

Previous CloseN/A

Volume76.75K

Average Volume (3M)1.96K

Market Cap

kr106.80M

Enterprise Valuekr68.70

Total Cash (Recent Filing)kr17.07M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.85

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding8,718,182

10 Day Avg. Volume1,714

30 Day Avg. Volume1,964

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)5.25

Price to Sales (P/S)0.00

P/FCF Ratio-3.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt materially reduces bankruptcy and interest-rate risk for a clinical-stage biotech. This structural strength preserves flexibility to fund trials via equity or partnerships without debt covenants, supporting longer-term project continuity and strategic optionality.

Focused Lead Asset On Vascular InjuryA single, well-defined lead program targeting endothelial damage and thrombo-inflammation aligns with a clear unmet medical need across multiple serious indications. This focused scientific positioning can drive durable clinical and commercial optionality if ANXV demonstrates efficacy, aiding partnerability.

Lean Organizational FootprintA very small headcount implies low fixed overhead and operational lean-ness, which can extend runway per financing and focus resources on core R&D. This structural efficiency supports disciplined cash use during multi-year clinical development phases, improving capital efficiency.

Bears Say

No Commercial Revenue (2020–2024)Absent any product revenue, the company is fully reliant on external financing or partnerships to fund operations. Over the medium term this increases dilution and execution risk, as sustainable operations hinge on uncertain clinical success or non-dilutive funding events.

Growing Cash Burn And Negative Free Cash FlowPersistently large and rising negative free cash flow signals heavy ongoing funding needs. Structurally, this forces repeated capital raises or deals, compresses management’s strategic flexibility, and increases the probability of dilution or unfavorable financing terms over the next 2–6 months.

Eroding Equity And Asset BaseA material decline in equity and total assets reflects cumulative losses and prior financing impacts. This erosion weakens the company’s capital buffer, reducing its ability to withstand trial setbacks, pursue parallel programs, or secure non-dilutive financing, constraining long-term resilience.

ANNX FAQ

What was Annexin Pharmaceuticals AB’s price range in the past 12 months?

Annexin Pharmaceuticals AB lowest stock price was kr11.05 and its highest was kr35.27 in the past 12 months.

What is Annexin Pharmaceuticals AB’s market cap?

Annexin Pharmaceuticals AB’s market cap is kr106.80M.

When is Annexin Pharmaceuticals AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Annexin Pharmaceuticals AB’s earnings last quarter?

Currently, no data Available

Is Annexin Pharmaceuticals AB overvalued?

According to Wall Street analysts Annexin Pharmaceuticals AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Annexin Pharmaceuticals AB pay dividends?

Annexin Pharmaceuticals AB does not currently pay dividends.

What is Annexin Pharmaceuticals AB’s EPS estimate?

Annexin Pharmaceuticals AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Annexin Pharmaceuticals AB have?

Annexin Pharmaceuticals AB has 8,718,182 shares outstanding.

What happened to Annexin Pharmaceuticals AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Annexin Pharmaceuticals AB?

Currently, no hedge funds are holding shares in SE:ANNX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.